WO2008027340A3 - Topical ophthalmic formulations - Google Patents

Topical ophthalmic formulations Download PDF

Info

Publication number
WO2008027340A3
WO2008027340A3 PCT/US2007/018850 US2007018850W WO2008027340A3 WO 2008027340 A3 WO2008027340 A3 WO 2008027340A3 US 2007018850 W US2007018850 W US 2007018850W WO 2008027340 A3 WO2008027340 A3 WO 2008027340A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
ophthalmic pharmaceutical
ophthalmic formulations
topical ophthalmic
active drug
Prior art date
Application number
PCT/US2007/018850
Other languages
French (fr)
Other versions
WO2008027340A2 (en
Inventor
Miller Ogidigben
Yu Ren
Original Assignee
Merck & Co Inc
Miller Ogidigben
Yu Ren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Miller Ogidigben, Yu Ren filed Critical Merck & Co Inc
Publication of WO2008027340A2 publication Critical patent/WO2008027340A2/en
Publication of WO2008027340A3 publication Critical patent/WO2008027340A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Abstract

This invention relates to ophthalmic pharmaceutical microsuspension formulations that drastically increase the ocular exposure of highly insoluble active drug agents, exhibit sufficient physical stability and permit easy re-dispersion of insoluble drug particles, thus yielding greater uniformity of drug dosing. This invention further relates to ophthalmic pharmaceutical vehicles and compositions comprising the vehicle and an active drug agent such as a low-solubility Maxi-K channel blocker.
PCT/US2007/018850 2006-08-30 2007-08-24 Topical ophthalmic formulations WO2008027340A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84114406P 2006-08-30 2006-08-30
US60/841,144 2006-08-30

Publications (2)

Publication Number Publication Date
WO2008027340A2 WO2008027340A2 (en) 2008-03-06
WO2008027340A3 true WO2008027340A3 (en) 2008-11-27

Family

ID=39136519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018850 WO2008027340A2 (en) 2006-08-30 2007-08-24 Topical ophthalmic formulations

Country Status (1)

Country Link
WO (1) WO2008027340A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009021372A1 (en) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphate-free pharmaceutical composition for glaucoma treatment
RU2012113380A (en) * 2009-09-07 2013-10-20 Микро Лабс Лимитед OPHTHALMIC COMPOSITIONS CONTAINING DORZOLAMIDE, THYMOL AND BRIMONIDINE
US8211450B2 (en) * 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
KR101119610B1 (en) * 2010-12-02 2012-03-06 한림제약(주) Opthalmic liquid composition comprising dorzolamide, timolol, and brimonidine
EA034839B1 (en) * 2014-10-20 2020-03-26 Сентисс Фарма Прайвет Лимитед Ophthalmic solution
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US6545036B2 (en) * 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US6545036B2 (en) * 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof

Also Published As

Publication number Publication date
WO2008027340A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008027341A3 (en) Topical ophthalmic formulations
WO2010047765A3 (en) Nanostructures for drug delivery
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
WO2008120207A3 (en) Compositions for nasal delivery
MX2010005013A (en) Intranasal compositions.
WO2008027340A3 (en) Topical ophthalmic formulations
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
TNSN08365A1 (en) Sustained release pharmaceutical composition on the basis of release system comprising an acid-soluble polymer and a ph-dependent polymer
BR112014031773A2 (en) biodegradable drug delivery for hydrophobic compositions
WO2007095041A3 (en) Pharmaceutical formulations
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2006060618A3 (en) Topical nepafenac formulations
WO2010080580A3 (en) Extended-release pharmaceutical formulations
MXPA05008913A (en) Stable ophthalmic formulation containing an antibiotic and a corticosteroid.
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2008003050A3 (en) Gallium nitrate formulations
WO2007092469A3 (en) Combination of organic compounds
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811551

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07811551

Country of ref document: EP

Kind code of ref document: A2